Use of Methazolamide to Lower Intraocular Pressure

Phase 4Active Not RecruitingNCT05498103

University of Colorado, Denver30 enrolled

Overview

The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Glaucoma, Open-Angle

Interventions

Methazolamide 25 MGDRUG

25 mg tablets

Methazolamide 50 MGDRUG

50 mg tablets

Eligibility

Sex: ALLMin age: 50 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females between 50 and 90 years old * Current diagnosis of open angle glaucoma (OAG) in both eyes * Ability to read and write in English Exclusion Criteria: * Glaucoma other than OAG * Severe or end-stage glaucoma (cup to disc ratio \>0.8 or Mean Deviation on Visual Field worse than -12) * Pregnant or breast-feeding women

Locations (1)

Sue Anschutz-Rodgers Eye Center

Aurora, Colorado, United States

Outcomes

Primary Outcomes

Percent IOP change at each follow-up Visit

IOP measure is measured using Goldmann Tonometry. IOP is measured in mmHg with a normal range from 12 mmHg to 22 mmHg.

Time frame: Day 1 (Pre-dosing, then 4- and 8- hours post dosing), Day 7 (Pre-dosing, then 4- and 8- hours post dosing), Day 14 (Pre-dosing, then 4- and 8- hours post dosing)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.